PROCEPT BioRobotics Reports Impressive Q3 Financial Performance
PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a leading surgical robotics company focused on advancing urological care, recently announced its financial results for the third quarter of fiscal year 2024. The company achieved total revenues of $58.4 million, marking a remarkable 66% increase compared to the same period in the previous year.
Performance Highlights for Q3 2024
The latest results showcase PROCEPT BioRobotics' continued growth and market penetration. Notably, in the U.S. market, the revenue generated from handpieces and consumables reached $29.6 million, showing an impressive 74% increase year-over-year. The sale of 45 robotic systems, with an average selling price close to $432,000, further underlines the growing acceptance and demand for advanced robotics in urology.
Revenue Breakdown and Growth Drivers
The company's overall U.S. revenue totaled $52.2 million for the third quarter, reflecting a growth of 62% compared to the prior year. This growth was largely attributed to robust sales of robotic systems, as well as an increase in the average selling prices and sales of consumables. Internationally, revenue also surged, totaling $6.2 million, which represents a staggering 122% increase from the third quarter of the previous year.
Record Gross Margins and Future Projections
PROCEPT BioRobotics achieved a record gross margin of 63.2% in the third quarter of 2024, a significant improvement from 53.8% in the previous year. This increase is primarily driven by enhanced overhead absorption alongside higher sales prices for their robotic systems. In response to this strong performance, the company has adjusted its revenue and Adjusted EBITDA guidance for the fiscal year 2024, raising the total revenue outlook to a range of $222.5 million to $223.0 million.
CEO Comments on Business Performance
Reza Zadno, the Chief Executive Officer of PROCEPT, expressed immense pride in the team’s accomplishments during this pivotal quarter. He highlighted the successful launch of the HYDROS system, following its FDA clearance, which played a crucial role in converting the capital pipeline while managing customer relationships during this critical phase of growth.
Financial Insights and Operating Expenses
The net loss for the third quarter was $21 million, an improvement over the $24.6 million loss reported in the same quarter last year. Adjusted EBITDA also showed progress, with a loss of $12.4 million for Q3 compared to $19.4 million in the previous year. The total operating expenses for the quarter increased to $59.3 million compared to $44.5 million in Q3 of 2023, reflecting the company’s investment in expanding its sales and marketing teams and enhancing research and development efforts.
Cash Position
As of the end of the third quarter, PROCEPT BioRobotics held cash, cash equivalents, and restricted cash totaling $199.8 million, positioning the company well for continued growth and innovation in the surgical robotics space.
Full Year 2024 Guidance
PROCEPT has increased its guidance for the full year 2024, projecting total revenue to be between $222.5 million and $223.0 million, which reflects a growth of approximately 63% to 64% compared to last year’s figures. The gross margin is expected to be around 61%, a slight increase from earlier estimates.
Conclusion and Future Outlook
The impressive results and updated guidance reflect PROCEPT BioRobotics' strong position in the market. The company's commitment to innovation and providing exceptional solutions for patients dealing with urological conditions continues to drive its success. With record revenue and optimized gross margins, PROCEPT is well on its path to achieving its ambitious financial goals for fiscal year 2024.
Frequently Asked Questions
What are the key highlights of PROCEPT BioRobotics' Q3 report?
The company reported $58.4 million in total revenue, a 66% increase from the previous year, alongside strong growth in handpiece and consumable sales.
What drove revenue growth for PROCEPT in Q3 2024?
Revenue growth was mainly driven by increased sales of robotic systems and higher average selling prices in addition to growing sales of consumables.
How did gross margins change for PROCEPT in Q3?
Gross margins improved to 63.2%, significantly higher than the 53.8% reported in the same quarter last year.
What is the updated financial guidance for PROCEPT for the full year 2024?
PROCEPT has updated its full-year revenue guidance to a range of $222.5 million to $223.0 million, reflecting year-over-year growth.
How is PROCEPT BioRobotics positioned for future growth?
With substantial cash reserves and an innovative product pipeline, PROCEPT BioRobotics is well-positioned for continued growth and market leadership in surgical robotics.
